FDA Approves GATTEX — Takeda Pharmaceuticals America, Inc.

On December 21, 2012, the FDA approved TEDUGLUTIDE (Subcutaneous), developed by Takeda Pharmaceuticals America, Inc., for the treatment of short bowel syndrome; the approval signaled the company's strategic entry into the critical pivotal care market for critically ill gastrointestinal patients, driving a substantial increase in share value.